Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest | Zendy

Philippe Moreillon | Zendy; Alain Bizzini | Zendy; Marlyse Giddey | Zendy; Jacques Vouillamoz | Zendy; José M. Entenza | Zendy

Open Access

Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest

Author(s) -

Philippe Moreillon,

Alain Bizzini,

Marlyse Giddey,

Jacques Vouillamoz,

José M. Entenza

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr521

Subject(s) - vancomycin , staphylococcus aureus , endocarditis , medicine , microbiology and biotechnology , staphylococcal infections , micrococcaceae , antibiotics , antibacterial agent , surgery , bacteria , biology , genetics

Laboratory detection of vancomycin-intermediate Staphylococcus aureus (VISA) and their heterogeneous VISA (hVISA) precursors is difficult. Thus, it is possible that vancomycin failures against supposedly vancomycin-susceptible S. aureus are due to undiagnosed VISA or hVISA. We tested this hypothesis in experimental endocarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research